A Prospective Study With Individually Adjusted High Dose 90Y-Ibritumomab Tiuxetan Treatment With Peripheral Blood Stem Cells Support to Improve Outcome for Patients With Refractory/Recurrent B-Cell Lymphoma, Stage II-IV.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibritumomab tiuxetan (Primary)
Indications B-cell lymphoma
Focus Adverse reactions
Acronyms HITT

Most Recent Events

16 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
12 Apr 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016 as per ClinicalTrials.gov record.
25 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Dec 2014.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight